Coronavirus Disease 2019 (COVID-19) Covid-19 Recovery

Frequently Asked Questions:  Drugs and Investigational Therapies

COVID-19 Risk

Q: Who is at chance appropriate to infection in the company of the virus that causes COVID-19?

A: Currently, those at greatest chance of infection are persons who have had prolonged, unprotected close contact in the company of a sick person in the company of symptomatic, long-established COVID-19 and those who live in or have recently been to areas in the company of sustained transmission. For additional information, perceive .

Q: If my sick person has one of the  listed, what is my patient’s chance and what should I tell my patient?

• There is insufficient information supported by COVID-19 to determine chance appropriate to each underlying medical condition. Epidemiologists at CDC are analyzing data around the clock to aid us additional precisely understand the risks of COVID-19. Information determination be present shared while soon while it’s available.
• You have knowledge of your sick person – their total health and how well their conditions are managed. Use your cold judgement to assess supported by a situation by situation basis.
• Tell patients in the company of that increase their chance of severe sickness or poorer outcomes from COVID-19:
  • To stay home as much while possible to reduce their chance of being exposed.
  • Encourage patients to closely follow their mind plans appropriate to management of their chronic disease, with better glycemic or blood pressure control.
• If possible, work in the company of patients to manage their underlying condition to the leading of their ability, with ensuring that patients have sufficient medication and supplies. Encourage everything patients, regardless of risk, to:
  • Take  to protect yourself.
  • Call your healthcare provider provided you are sick in the company of a fever, cough, or shortness of breath.
  • Follow CDC  and the recommendations of your state and local health officials.
• Fear and uneasiness about a disease can feel overwhelming, especially appropriate to those who might be present at higher chance or are experiencing social isolation, and appropriate to healthcare providers that are treating patients at higher risk.

Q: Are pregnant healthcare personnel at increased chance appropriate to adverse outcomes provided they mind appropriate to patients in the company of COVID-19?

A: Pregnant healthcare personnel (HCP) should follow  guidelines appropriate to HCP exposed to patients in the company of suspected or long-established COVID-19. Adherence to recommended infection prevention and control practices is an important part of protecting everything HCP in healthcare settings. Information supported by COVID-19 in pregnancy is very limited; facilities may desire to consider limiting exposure of pregnant HCP to patients in the company of long-established or suspected COVID-19, especially throughout higher chance procedures (e.g., aerosol-generating procedures) provided possible based supported by staffing availability.

Transmission

Q: When is someone infectious?

A: The beginning and length of viral shedding and the period of infectiousness appropriate to COVID-19 are not yet known. It is possible that SARS-CoV-2 RNA may be present detectable in the upper or lower respiratory tract appropriate to weeks after sickness onset, similar to infections in the company of MERS-CoV and SARS-CoV. However, spotting of viral RNA does not necessarily mean that infectious virus is present. There are reports of asymptomatic infections (detection of virus in the company of no increase of symptoms) and pre-symptomatic infections (detection of virus prior to increase of symptoms) in the company of SARS-CoV-2, however their part in transmission is not yet known. Based supported by existing literature, the incubation period (the time from exposure to increase of symptoms) of SARS-CoV-2 and additional coronaviruses (e.g. MERS-CoV, SARS-CoV) ranges from 2–14 days.

Q: Which body fluids can open (out) infection?

A: SARS-CoV-2 RNA has been detected in upper and lower respiratory tract specimens, and SARS-CoV-2 virus has been isolated from upper respiratory tract specimens and bronchoalveolar lavage fluid. SARS-CoV-2 RNA has been detected in blood and stool specimens, and SARS-CoV-2 virus has been isolated in cell culture from the stool of some patients, with a sick person in the company of pneumonia 15 days after symptom onset. The length of SARS-CoV-2 RNA spotting in upper and lower respiratory tract specimens and in extrapulmonary specimens is not yet famous however may be present several weeks or longer. Duration of several week or longer has been observed in cases of MERS-CoV or SARS-CoV infection. While viable, infectious SARS-CoV has been isolated from respiratory, blood, urine, and stool specimens, viable, infectious MERS-CoV has only been isolated from respiratory tract specimens. It is not yet famous whether additional non-respiratory body fluids from an infected person with vomit, urine, breast milk, or semen can contain viable, infectious SARS-CoV-2.

Q: Can people who recover from COVID-19 be present re-infected in the company of SARS-CoV-2?

A: The immune response, with length of immunity, to SARS-CoV-2 infection is not yet understood. Patients in the company of MERS-CoV are unlikely to be present re-infected shortly after they recover, however it is not yet famous whether similar immune protection determination be present observed appropriate to patients in the company of COVID-19.

Testing, Diagnosis, and Notification

Q: How do you test a sick person appropriate to infection in the company of SARS-CoV-2?

• Clinicians are able to access laboratory trying through a network of state and local public health laboratories across the country. The .
• Several cold laboratories are receiving authorization appropriate to trying from the U.S. Food and Drug Administration (FDA) below an Emergency Use Authorization. They are anticipated to be present able to offer a larger volume of trying appropriate to COVID-19. You can contact your current laboratory vendor to find out when the test determination be present available.
• There are a number of commercially available SARS-CoV-2 diagnostic assays that have received .
• See recommendations appropriate to reporting, testing, and specimen collection at .

Q: Do existing commercially available multiple respiratory virus panels, such while those manufactured by Biofire or Genmark, detect SARS-CoV-2?

A: Not currently. These multi-pathogen molecular assays can detect a number of human respiratory viruses, with additional human coronaviruses that can cause acute respiratory illness, however they do not currently detect SARS-CoV-2. In the future, it is anticipated that these assays determination have the ability to detect SARS-CoV-2 in respiratory specimens.

Q: If a sick person tests positive appropriate to another respiratory virus, should that exclude SARS-CoV-2 while a cause of illness?

A: Patients can be present infected in the company of additional than one virus at the same time. Coinfections in the company of additional respiratory viruses in people in the company of COVID-19 have been reported. Therefore, identifying infection in the company of one respiratory virus does not exclude SARS-CoV-2 virus infection.

Q: Should chest CT be present used appropriate to identification of COVID-19?

A: Clinicians considering use of chest CT scans appropriate to identification or management of COVID-19 patients should consider whether such imaging determination change cold management. The American College of Radiology (ACR) recommends that CT should not be present used to screen appropriate to COVID-19, or while a first-line test to diagnose COVID-19, and that CT should be present used sparingly and reserved appropriate to hospitalized, indicative patients in the company of specific cold indications appropriate to CT. Appropriate infection control procedures should be present followed before scanning subsequent patients. For additional information see, .

Q: Whom should healthcare providers notify provided they suspect a sick person has COVID-19?

A: Healthcare Providers should immediately notify infection control personnel at their facility provided they suspect COVID-19 in a patient. Providers should in those days consult in the company of local or state health departments to determine whether patients meet criteria appropriate to a Persons Under Investigation (PUI), perceive .

Treatment and Management

Q: How are COVID-19 patients treated?

A: Not everything patients in the company of COVID-19 determination require medical helpful care. Clinical management appropriate to hospitalized patients in the company of COVID-19 is focused supported by helpful mind appropriate to complications, with supplemental oxygen and advanced organ support appropriate to respiratory failure, septic shock, and multi-organ failure. Empiric trying and medical care appropriate to additional viral or bacterial etiologies may be present warranted.

Corticosteroids are not routinely recommended appropriate to medical care of viral pneumonia or ARDS, due to the potential appropriate to prolonging viral replication, while has been observed in the company of MERS coronavirus and influenza. Corticosteroids should be present avoided unless they are indicated appropriate to another reason (e.g., COPD exacerbation or difficult septic shock following the ).

For information supported by investigational therapies, perceive .

Drugs and Investigational Therapies

Q: Should angiotensin converting enzyme inhibitors (ACE-I) or Angiotensin Receptor Blockers (ARB) be present stopped in patients in the company of COVID-19?

A: CDC is currently not aware of scientific proof establishing a connection between ACE-I or ARBs and chance of contracting or severity of COVID-19. The American Heart Association, the Heart Failure Society of America, and the American College of Cardiology continuation of ACE-I or ARB medications appropriate to everything patients already prescribed those medications appropriate to indications such while heart failure, hypertension, or ischemic heart disease. Cardiovascular disease patients who are diagnosed in the company of COVID-19 should be present fully evaluated by a healthcare professional before adding or removing a bit of treatments, and a bit of changes to their medical care should be present based supported by the latest scientific evidence. Patients who rely supported by ACE-I or ARBs to treat chronic conditions and have more questions should speak to their healthcare provider appropriate to individualized management.

Q: Do nonsteroidal anti-inflammatory drugs (NSAIDs) worsen the course of disease appropriate to people in the company of COVID-19?

A: CDC is currently not aware of scientific proof establishing a connection between NSAIDs (e.g., ibuprofen, naproxen) and worsening of COVID‑19. , and CDC are continuing to monitor the situation and determination review new information supported by the effects of NSAIDs and COVID-19 disease while it becomes available. For those who wish to use medical care options additional than NSAIDs, there are additional over-the-counter and prescription medications approved appropriate to pain relief and fever reduction. Patients who rely supported by NSAIDs to treat chronic conditions and have more questions should speak to their healthcare provider appropriate to individualized management. Patients should use NSAIDs, and everything medications, according to the produce labels and advice of their healthcare professional.

Waste Management

Q: What do waste management companies miss to have knowledge of about wastewater and sewage coming from a healthcare facility or community setting in the company of either a famous COVID-19 sick person or person below investigation (PUI)?

A: Waste generated in the mind of PUIs or patients in the company of long-established COVID-19 does not present more considerations appropriate to wastewater disinfection in the United States. Coronaviruses are susceptible to the same disinfection conditions in community and healthcare settings while additional viruses, thus current disinfection conditions in wastewater medical care facilities are anticipated to be present sufficient. This includes conditions appropriate to practices such while oxidation in the company of hypochlorite (i.e., chlorine bleach) and peracetic acid, while well while inactivation using UV irradiation.

Q: Do wastewater and sewage workers miss a bit of more protection when handling untreated waste from healthcare or community setting in the company of either a famous COVID-19 sick person or PUI?

A: Wastewater workers should use standard practices including  as prescribed appropriate to their current work tasks when handling untreated waste. There is no proof to suggest that employees of wastewater plants miss a bit of more protections in relation to COVID-19.

Q: Should medical waste or general waste from healthcare facilities treating PUIs and patients in the company of long-established COVID-19 be present handled a bit of differently or miss a bit of more disinfection?

A: Medical waste (trash) coming from healthcare facilities treating COVID-2019 patients is no different than waste coming from facilities without COVID-19 patients. CDC’s guidance states that management of laundry, food service utensils, and medical waste should be present performed in accordance in the company of routine procedures. There is no proof to suggest that facility waste needs a bit of more disinfection.

More guidance about environmental infection control is available in section 7 of CDC’s  for Patients in the company of Confirmed COVID-19 or Persons Under Investigation appropriate to COVID-19 in Healthcare Settings.

 

Share this post